Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SOCMA urges EPA to revise costly area sources rulemaking
On March 3, SOCMA members and staff met with key EPA staff in North Carolina to discuss the chemical manufacturing area sources proposed rule. The meeting concluded with
On March 3, SOCMA members and staff met with key EPA staff in North Carolina to discuss the chemical manufacturing area sources proposed rule. The meeting concluded with
The growth and development of nanotechnology now includes a broad range of companies engaged in the production and use of nanoscale materials. Nanotech startups and other companies associated
Nobilon, the human vaccine business unit of Schering-Plough, has initiated its first-in-human clinical development program for SCH 900795, a new intranasal live attenuated influenza vaccine for annual seasonal
Takeda Pharmaceutical Company has launched Ecard, a fixed dose combination tablet of Blopress and a low-dose diuretic for treatment of hypertension. According to Takeda, Ecard is a fixed
YM BioSciences, an oncology product development company, has enrolled the first patient into its multinational trial of nimotuzumab for the treatment of patients with non-small-cell lung cancer. This
NeoMatrix, a medical device company, has completed its C2 funding round totaling $15m. This figure is, due to overwhelming investor demand, 50% more than the company’s initial target
Repros Therapeutics, a developer of oral small molecule drugs, has reported net loss of $5.86m or $0.39 per share, for the three-month period ended December 31, 2008, compared
Synta Pharmaceuticals, a biopharmaceutical company, has reduced its workforce by approximately 90 positions, to a total of approximately 130 positions, allowing the company to operate with current cash
The company recorded a loss of C$6.57 million, or C$0.13 per share, for the six-month period ended January 31, 2009, compared to a loss of C$3.17 million, or
Net loss for the year ended December 31, 2008, was $9.13 million, or $0.38 per share, compared with a net loss of $7.28 million, or $0.31 per share,